
CLAIMS

1. A compound of Formula I or a pharmaceutically acceptable salt thereof,



I ;

wherein

Z is OR_a, NR_aR_b, or $NR_b(C=O)R_a$;

X_1 is alkyl, halogenated alkyl, cycloalkyl, cycloalkenyl, halogenated cycloalkyl, H, halogen, or CN;

X_2 is halogen, CN, alkyl, halogenated alkyl, cycloalkyl, halogenated cycloalkyl, or H;

X_3 is H, halogen, fluorinated alkyl, or alkyl;

or alternatively X_1 and X_2 and the carbon atoms they are connected to taken together form an optionally substituted 6-membered aryl;

or alternatively X_2 and X_3 and the carbon atoms they are connected to taken together form an optionally substituted 6-membered aryl;

R_3 is H, halogen, or alkyl;

or alternatively X_1 and R_3 and the carbon atoms they are connected to taken together form an optionally substituted 6-membered aryl;

R_1 and R_2 are each independently H, alkyl, $(CR_6R_7)_{n4}OR_a$, $(CR_6R_7)_{n4}NR_aR_b$, $(CR_6R_7)_{n4}NR_a(C=O)R_b$, $(CR_6R_7)_{n4}NR_aSO_2R_b$, or $(CR_6R_7)_{n4}CONR_aR_b$, wherein at least one occurrence of R_1 and R_2 is $(CR_6R_7)_{n4}NR_aR_b$, $(CR_6R_7)_{n4}OR_a$, $(CR_6R_7)_{n4}NR_a(C=O)R_b$, $(CR_6R_7)_{n4}NR_aSO_2R_b$, or $(CR_6R_7)_{n4}CONR_aR_b$; or alternatively R_1, R_2 and the carbon atom they are connected to taken together form a 3-5 membered carbocycle;

R_4 is $(CR_6R_7)_{n4}(C=O)R_c$, $(C=O)(CR_6R_7)_{n4}R_c$, $(CR_6R_7)_{n4}OR_c$, $(CR_6R_7)_{n4}COOR_c$, $(CR_6R_7)_{n4}NR_c(C=O)R_d$, $(CR_6R_7)_{n4}(C=O)NR_cR_d$, $(C=O)(CR_6R_7)_{n4}NR_cR_d$,

$(CR_6R_7)_{n4}(C=O)(C=O)NR_cR_d$, $(C=O)(CR_6R_7)_{n4}OR_c$, $(CR_6R_7)_{n4}SO_2R_c$, $(CR_6R_7)_{n4}SO_2NR_cR_d$, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -alkyl-aryl, optionally substituted -alkyl-heteroaryl, optionally substituted -alkyl-heterocycle, optionally substituted cycloalkyl, optionally substituted -alkyl-cycloalkyl, or optionally substituted -cycloalkyl-alkyl;

each occurrence of R_5 is independently H, alkyl, cycloalkyl, or oxo;

or two R_5 groups taken together with the carbon atom(s) that they are connected to form a 3-7 membered optionally substituted saturated carbocycle;

or two R_5 groups are connected to different carbon atoms on the ring and taken together form a bond or an alkyl chain containing 1-3 carbons;

each occurrence of R_6 and R_7 are independently H, alkyl, or cycloalkyl;

each occurrence of R_a and R_b are independently H, alkyl, cycycloalkyl, saturated heterocycle, aryl, or heteroaryl; or alternatively R_a and R_b together with the nitrogen atom that they are connected to form an optionally substituted heterocycle comprising the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S;

each occurrence of R_c and R_d are independently H, alkyl, alkyl substituted by 1-4 substituents each of which is independently halogen, OR_8 or $N(R_8)_2$, alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -alkyl-aryl, optionally substituted -alkyl-heteroaryl, optionally substituted -alkyl-heterocycle, optionally substituted -alkyl-cycloalkyl, or optionally substituted -cycloalkyl-alkyl; or alternatively R_c and R_d together with the nitrogen atom that they are connected to form an optionally substituted heterocycle comprising the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S;

each occurrence of R_8 is independently H, alkyl, or an optionally substituted heterocycle; or alternatively the two R_8 groups together with the nitrogen atom that they are connected to form an optionally substituted heterocycle comprising the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S;

R_9 is H, alkyl, halogen, or $(CR_6R_7)_{n4}OR_b$;

the alkyl, cycloalkyl, spiroalkyl, bicycloalkyl, heterocycle, aryl, and heteroaryl in X_1, X_2, X_3, R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_9, R_a, R_b, R_c, and R_d, where applicable, are optionally substituted by 1-4 substituents each independently selected from the group consisting of alkyl, cycloalkyl, halogenated cycloalkyl, halogenated alkyl, halogen, CN, $-(CH_2)_{0-2}OR_8$, $N(R_8)_2$, $(C=O)C_{1-4}$alkyl, $(C=O)N(R_8)_2$, and oxo where valence permits;







each occurrence of n_1 is independently an integer from 0-3 where valence permits;





each occurrence of n_2 and n_3 is independently an integer from 0-3; and



each occurrence of n_4 is independently an integer from 0-3.

2. The compound of claim 1, wherein:

(a) each occurrence of n_2 and n_3 is independently an integer from 0-1; or

(b) the structural motif  has the structure of , , , , or ; or

(c) the structural motif  has the structure of , , or ; or

(d) the structural motif  has the structure of .

3. The compound of claim 1 or 2, wherein at least one occurrence of R_1 and R_2 is $(CR_6R_7)_{n4}OR_a$, $(CR_6R_7)_{n4}NR_aR_b$, $(CR_6R_7)_{n4}NR_a(C=O)R_b$, $(CR_6R_7)_{n4}NR_aSO_2R_b$, or $(CR_6R_7)_{n4}CONR_aR_b$.

4. The compound of claim 3, wherein at least one occurrence of R_1 and R_2 is OR_a or NR_aR_b.

5. The compound of claim 1 or 2, wherein R_1, R_2, and the carbon atom they are connected to taken together form a 3-5 membered carbocycle.

6. The compound of any one of claims 1-5, wherein:

(a) R_4 is $(CR_6R_7)_{n4}OR_c$, $(CR_6R_7)_{n4}COR_c$, $(C=O)(CR_6R_7)_{n4}R_c$, $(CR_6R_7)_{n4}COOR_c$, $(CR_6R_7)_{n4}NR_c(C=O)R_d$, $(CR_6R_7)_{n4}(C=O)NR_cR_d$, $(CR_6R_7)_{n4}(C=O)(C=O)NR_cR_d$, $(C=O)(CR_6R_7)_{n4}OR_c$, $(CR_6R_7)_{n4}SO_2R_c$, or $(CR_6R_7)_{n4}SO_2NR_cR_d$; or





























(b) R_4 is $(CR_6R_7)_2OR_c$, $(C=O)R_c$, $(C=O)(CR_6R_7)_{1-2}R_c$, $COOR_c$, $(CR_6R_7)_{1-2}NR_c(C=O)R_d$, $(C=O)NR_cR_d$, $(CR_6R_7)_{n4}(C=O)(C=O)NR_cR_d$, $(C=O)(CR_6R_7)_{1-2}OR_c$, SO_2R_c, or $SO_2NR_cR_d$; or





(c) R_4 is $(CH_2)_2OH$, $(CH_2)_2OMe$, $(C=O)H$, $(C=O)Me$, $(C=O)CH_2OH$, $(C=O)CH_2OMe$, $(C=O)Et$, $(C=O)Ph$, $(C=O)$isopropyl, $(C=O)NH_2$, $(C=O)NHMe$, $(C=O)NMe_2$, $(C=O)CH_2NH_2$, $(C=O)CH_2NHMe$, $(C=O)CH(OH)CH_2OH$, $(C=O)CH(OMe)CH_2OH$, $(C=O)CH(OH)CH_2OMe$, $(C=O)(C=O)NMe_2$, $(C=O)OMe$, SO_2Me, SO_2Et, SO_2CH_2OH, SO_2CH_2OMe, SO_2NH_2, SO_2NHMe, or SO_2NMe_2; or


(d) R_4 is $(C=O)R_c$, $(C=O)(CR_6R_7)_{1-2}R_c$, $(C=O)(CR_6R_7)_{1-2}OR_c$, or SO_2R_c; and wherein R_c is selected from the group consisting of H, alkyl, alkyl substituted by 1-4 substituents each

independently selected from the group consisting of halogen, OR_8 and $N(R_8)_2$, alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -alkyl-aryl, optionally substituted -alkyl-heteroaryl, optionally substituted -alkyl-heterocycle, optionally substituted -alkyl-cycloalkyl, and optionally substituted -cycloalkyl-alkyl.

7. The compound of any one of claims 1-5, wherein R_4 is $(CR_6R_7)_2OR_c$, $(C=O)R_c$, $(C=O)(CR_6R_7)_{1-2}R_c$, $COOR_c$, $(CR_6R_7)_{1-2}NR_c(C=O)R_d$, $(C=O)NR_cR_d$, $(CR_6R_7)_{n4}(C=O)(C=O)NR_cR_d$, $(C=O)(CR_6R_7)_{1-2}OR_c$, SO_2R_c, or $SO_2NR_cR_d$, and:

(a) R_c or R_d is H, Me, Et, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ; or


(b) R_c or R_d is a heterocycle selected from the group consisting of , , , , , , , , , , , , , , , , , , , , , , .



; wherein the heterocycle is optionally substituted by one or more cyano, cycloalkyl, fluorinated alkyl, fluorinated cycloalkyl, halogen, OH, NH_2, oxo, or $(C=O)C_{1-4}$alkyl where valence permits; or


(c) R_c is cycloalkyl, spiroalkyl, or bicycloalkyl each optionally substituted by 1-4 substituents each independently selected from the group consisting of alkyl, halogen, CN, -


$(CH_2)_{0-2}OR_8$, $N(R_8)_2$, $(C=O)N(R_8)_2$, and oxo where valence permits; or

(d) R_c is , each optionally substituted by 1-4 substituents each independently selected from the group consisting of alkyl, halogen, CN, -$(CH_2)_{0-2}OR_8$, $N(R_8)_2$, $(C=O)N(R_8)_2$, and oxo where valence permits.

8. The compound of any one of claims 1-5, wherein:


(a) R_4 is optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -alkyl-aryl, optionally substituted -alkyl-heteroaryl, optionally substituted -alkyl-heterocycle, optionally substituted cycloalkyl, optionally substituted -alkyl-cycloalkyl, or optionally substituted -cycloalkyl-alkyl; or









































(b) R_4 is a heterocycle selected from the group consisting of ,




; wherein the heterocycle is optionally substituted by one or more cyano, cycloalkyl, fluorinated alkyl, fluorinated cycloalkyl, halogen, OH, NH_2, oxo, or $(C=O)C_{1-4}$alkyl where valence permits; or

(c) R_4 is cycloalkyl optionally substituted by 1-4 substituents each independently selected from the group consisting of alkyl, halogen, CN, $-(CH_2)_{0-2}OR_8$, $N(R_8)_2$, $(C=O)N(R_8)_2$, and oxo where valence permits; or

(d) R_4 is  each optionally substituted by 1-4 substituents each independently selected from the group consisting of alkyl, halogen, CN, $-(CH_2)_{0-2}OR_8$, $N(R_8)_2$, $(C=O)N(R_8)_2$, and oxo where valence permits.

9. The compound of any one of claims 1-5, wherein R_4 is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

, or a tautomer thereof.

10. The compound of any one of claims 1-9, wherein:

(a) at least one occurrence of R_5 is H, alkyl or cycloalkyl; or

(b) at least one occurrence of R_5 is oxo; or

(c) two R_5 groups are connected to different carbon atoms on the ring and taken together form a bond or an alkyl chain containing 1-3 carbons; or

(d) two R_5 groups taken together with the carbon atom(s) that they are connected to form a 3-7 membered optionally substituted saturated carbocycle.

11. The compound of any one of the preceding claims, wherein:

(a) at least one of R_a and R_b is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl; or

(b) R_a and R_b together with the nitrogen atom that they are connected to form an optionally substituted heterocycle comprising the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S.

12. The compound of any one of the preceding claims, wherein:

(a) each occurrence of R_6 and R_7 are independently H or alkyl; and/or

(b) R_9 is (i) H, alkyl, or halogen, or (ii) $(CR_6R_7)_{n4}OR_b$; or (iii) H, F, or OH.

13. The compound of any one of the preceding claims, wherein:

(a) Z is OH, OMe, NH_2, NHMe, or NMe_2; or

(b) Z is OH.

14. The compound of any one of the preceding claims, wherein:

(a) X_1 is Me or Cl; or

(b) X_1 is H, halogen, fluorinated alkyl or alkyl; or

(c) X_1 is H, F, Cl, Br, Me, CF_3, or CF_2Cl.

15. The compound of any one of the preceding claims, wherein:

(a) X_2 is Cl; or









(b) X_2 is H, halogen, fluorinated alkyl or alkyl; or

(c) X_2 is H, F, Cl, Br, Me, CF_3, or CF_2Cl.


16. The compound of any one of the preceding claims, wherein:


(a) X_3 is H, F, Cl, Br, fluorinated alkyl, or alkyl; or

(b) X_3 is H, F, Cl, or CF_3.

17. The compound of any one of claims 1-12, wherein the structural moiety  has the structure of , , , , , , or , each of which is substituted by R_3, optionally wherein R_3 is (a) H or alkyl or (b) halogen.

18. The compound of any one of the preceding claims, wherein:

(a) at least one occurrence of R_8 is H, alkyl, or optionally substituted heterocycle, optionally wherein R_8 is H, Me, Et, Pr, Bu, or a heterocycle selected from the group consisting of 




; wherein the heterocycle is optionally substituted by one or more cyano, cycloalkyl, fluorinated alkyl, fluorinated cycloalkyl, halogen, OH, NH_2, oxo, or $(C=O)C_{1\text{-}4}$alkyl where valence permits; or

(b) the two R_8 groups together with the nitrogen atom that they are connected to form an optionally substituted heterocycle comprising the nitrogen atom and 0-3 additional heteroatoms

each selected from the group consisting of N, O, and S.





19. The compound of any one of claim 1-5, wherein:





(a) at least one occurrence of R_c or R_d is independently H, alkyl, alkyl substituted by 1-4 substituents each independently selected from the group consisting of halogen, OR_8 and $N(R_8)_2$, alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -alkyl-aryl, optionally substituted -alkyl-heteroaryl, optionally substituted -alkyl-heterocycle, optionally substituted -alkyl-cycloalkyl, or optionally substituted -cycloalkyl-alkyl; or









(b) at least one occurrence of R_c or R_d is independently H, Me, Et, , or .









20. The compound of claim 1, wherein the compound is selected from a group consisting of compounds 1-338 in Table 1.








21. The compound of claim 1, wherein the compound is selected from the group consisting of the following compounds and pharmaceutically acceptable salts thereof









Structure















Structure















Structure



















Structure

















Structure















Structure



















Structure




















Structure




















Structure


















Structure

















Structure

















Structure





















Structure



















Structure



















Structure


















Structure

















Structure



















Structure



















Structure

















Structure

















Structure




















Structure



















Structure



















Structure


















Structure












Structure













Structure















Structure
















Structure















Structure














Structure












Structure














Structure














Structure













Structure












Structure











Structure













Structure















Structure
















Structure








Structure







Structure







Structure






Structure







Structure	Structure
	
	
	
	

.

22. A pharmaceutical composition comprising at least one compound according to any one of claims 1-21 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

23. A compound according to any one of claims 1-21 for use as a medicament.

24. Use of a compound according to any one of claims 1-21 in the manufacture of a medicament for treating a condition in a mammalian species in need thereof, the medicament comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable

salt thereof, wherein the condition is selected from the group consisting of cancer, an immunological disorder, a Central Nerve System (CNS) disorder, an inflammatory disorder, a gastroenterological disorder, a metabolic disorder, a cardiovascular disorder, and a kidney disease;

optionally wherein the condition is:

(a) an immunological disorder that is transplant rejection or an autoimmune disease, wherein the autoimmune disease is optionally rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or Type I diabetes mellitus; or

(b) a Central Nerve System (CNS) disorder that is Alzheimer's disease;

(c) an inflammatory disorder that is an inflammatory skin condition, arthritis, psoriasis, spondylitis, parodontitits, or an inflammatory neuropathy;

(d) an gastroenterological disorder that is an inflammatory bowel disease; or

(e) a metabolic disorder that is obesity or Type II diabetes mellitus; or

(f) a cardiovascular disorder that is an ischemic stroke; or

(g) a kidney disease that is chronic kidney disease, nephritis, or chronic renal failure; or

(h) selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Type I diabetes mellitus, Alzheimer's disease, inflammatory skin condition, inflammatory neuropathy, psoriasis, spondylitis, parodontitis, Crohn's disease, ulcerative colitis, obesity, Type II diabetes mellitus, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and a combination thereof;

and optionally wherein the mammalian species is human.